BIO-TECH SYSTEMS, INC.
Market Research in the Health Care Field
NEWS RELEASE 4167 Pinecrest Circle West
───────────────── ...
The high pricing of these products is justified by their unique status and is indicative of future
market opportunities, e...
DIAGNOSTIC RADIOPHARMACEUTICALS: REPORT CONTENTS
SECTION I: Market Status, Trends and Forecasts
Analysis of recent sales, ...
PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS
HISTORICAL AND FORECAST GROWTH OF
RADIOPHARMACEUTICAL SALES FROM
...
PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS
2002 SALES OF TECHNETIUM
GENERATORS, RADIOPHARMACEUTICAL
SUPPLIER...
THERAPEUTIC RADIOPHARMACEUTICALS: REPORT CONTENTS
SECTION I: Market Status, Trends and Forecasts
Analysis of current and e...
PARTIAL LIST OF EXHIBITS: THERAPEUTIC RADIOPHARMACEUTICALS
HISTORIC AND FORECAST SALES GROWTH
OF THERAPEUTIC RADIOPHARMA-
...
COMPANY PROFILES INCLUDE
AMERSHAM HEALTH
ANTISOMA, LTD. (UK)
BERLEX LABORATORIES
CIS BiO-INTERNATIONAL (BERLEX)
DIATIDE RE...
ORDER FORM
Report No. 150 — THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS
Report No. 160 — THE U.S. MARKET FOR THERA...
ORDER FORM
Report No. 150 — THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS
Report No. 160 — THE U.S. MARKET FOR THERA...
Upcoming SlideShare
Loading in …5
×

Newsletter-Radiopharmaceutical_Reports.doc

454 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
454
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
7
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Newsletter-Radiopharmaceutical_Reports.doc

  1. 1. BIO-TECH SYSTEMS, INC. Market Research in the Health Care Field NEWS RELEASE 4167 Pinecrest Circle West ───────────────── Las Vegas, Nevada 89121 June 1, 2003 ───────────────────────── (702) 456-7608 (702) 456-2189 FAX E-Mail: MBurns@biotechsystems.com Web Site: http://www.biotechsystems.com ─────────────────────────────────────────────────────────────────────────────── FOR IMMEDIATE RELEASE Contact: Marvin Burns Tel: (702) 456-7608 Fax: (702) 456-2189 BIO-TECH SYSTEMS ANNOUNCES THE RELEASE OF TWO NEW REPORTS: Report 150: THE U.S MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS Report 160: THE U.S MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS ────────────────────────────────────────────────────────────── PRESENT AND EMERGING MARKET OPPORTUNITIES, NEW HIGH GROWTH PROSPECTS IN IMAGING AND THERAPY, TECHNOLOGICAL TRENDS AND COMPETITIVE CHALLENGES, INDUSTRY ANALYSIS AND SALES FORECASTS Bio-Tech Systems Inc. announces the publication of two comprehensive reports with detailed analysis of the markets for diagnostic and therapeutic radiopharmaceuticals. The diagnostic markets cover nuclear cardiology, neurology, functional nuclear medicine, targeted oncology and PET imaging. Therapeutic radiopharmaceuticals include both current and emerging applications for lymphoma colon cancer, lung cancer, bone cancer, endocrine cancer, brain cancer, liver cancer, pancreatic cancer and other cancers resistant to traditional therapies. Confidence in the prospects for therapeutic radiopharmaceuticals has overlapped into the diagnostic market, creating a stronger link between targeted imaging and complementary therapeutic products based on the same antibody or peptide. This has been a boon to nuclear medicine, since nuclear imaging is required in all cases to assess biodistribution and dosing of therapeutic radiopharmaceuticals, as well as evaluate patient response to therapy. Both reports have a strong focus on new products and technology and emerging market opportunities. Many of the new diagnostic agents have a therapeutic counterpart, allowing nuclear imaging, with feedback with respect to targeting. In addition, new diagnostic products in cardiology, neurology and functional nuclear medicine are also covered in detail. This includes novel approaches to assessing myocardial viability and infection imaging, as well as new products in neurology for diagnosing Parkinson’s and related neurological disorders The prospects for therapeutic radiopharmaceuticals are also on a major threshold with the approval of Zevalin for non-Hodgkins lymphoma. This will be followed by other radiotherapy products for both circulating and solid tumors, which should form a sound base for continued investment in this field. As these products enter the mainstream, there will be others in the pipeline for treating a variety of cancers. One motivator is the potential return on investment. 1 ---more---
  2. 2. The high pricing of these products is justified by their unique status and is indicative of future market opportunities, even in the presence of competition. Diagnostic Radiopharmaceuticals: Market Analysis and Future Prospects U.S. sales of diagnostic radiopharmaceuticals reached $1.14 billion in 2002 and are expected to rise to $2.94 billion by 2008. Radiopharmaceutical sales grew 15% in 2002 and should increase to 20% by 2004-2005. This growth will be based on introduction of new products, strong demand for cardiology procedures and increased sales of oncology products, particularly FDG for PET imaging. Market growth should also benefit from higher prices for these new products. In addition, more biopharmaceutical products will incorporate monoclonal antibody and peptide- based targeted agents, expanding the range of nuclear procedures. This technical influx will help all segments of nuclear medicine as nuclear imaging and therapy move closer together. One effect is that clinicians will have more options as alternatives to higher risk and more costly invasive procedures. This will stimulate more research and investment, adding strength and stability to newer venture companies as well as those more established in the field. Therapeutic Radiopharmaceuticals: Market Analysis and Future Prospects U.S. sales of therapeutic radiopharmaceuticals were on the threshold in 2002 with the approval of Zevalin for non-Hodgkins lymphoma. Total therapeutic product sales were $57 million in 2002, with rapid growth anticipated over the next 5-6 years. By 2008, therapeutic product sales should reach $3.80 billion, exceeding diagnostic radiopharmaceutical sales by 30%. This will be based on the introduction of new therapeutic radiopharmaceuticals for treating lymphoma, colon cancer, lung cancer, bone cancer and other persistent cancers. These agents will be used in conjunction with traditional therapies, enhancing their effectiveness, with better specificity and reduced side effects. As interest in new therapeutic radiopharmaceuticals increases, it will prompt investigators to consider different isotopes with more focused capabilities for treating various tumors, reducing the bystander effect on neighboring healthy cells. Use of these new agents will reduce treatment time and accelerate recovery for many patients. It will also offer an attractive investment opportunity for many of the companies and venture groups supporting these programs. ABOUT THE AUTHOR Marvin Burns is president of Bio-Tech Systems, Inc., a firm that focuses on market research in the healthcare field. Burns specializes in market evaluation, where technological and scientific insight is important. The company has prepared numerous market research reports on diagnostic and therapeutic radiopharmaceuticals, brachytherapy, contrast media, interventional cardiology and medical imaging, which have been widely distributed. Burns has also served as a consultant to many international firms and venture groups in these fields. He has also been Technology Editor of Future Oncology, a publication widely circulated in the pharmaceutical and biotechnology industry reporting on new developments in cancer diagnosis and treatment. Burns is a graduate of MIT and Harvard Business School’s advanced management program. He has prepared over 100 publications and has 15 patents and invention disclosures. Prior to forming Bio-Tech Systems, he was employed by firms in life sciences, bioinstrumentation and medical imaging fields in general management, marketing and product development. He was also a hospital administrator in charge of professional and technical services including medical imaging, clinical laboratories, therapy services, and materials management. 2 ---more---
  3. 3. DIAGNOSTIC RADIOPHARMACEUTICALS: REPORT CONTENTS SECTION I: Market Status, Trends and Forecasts Analysis of recent sales, competitive challenges, new products in the pipeline and forces affecting future growth. Also provides sales forecasts to 2008. Products include: • Nuclear cardiology (heart perfusion agents, pharmacologic stressors, blood pool agents, myocardial viability agents, thrombus imaging and metabolic FDG imaging. • Functional nuclear medicine and cancer imaging (antibody and peptide-based products, NeoTect, ProstaScint, AcuTect, Octreoscan, CEA-Scan and FDG imaging. • Neurology Imaging (New products for Parkinson’s and related syndromes, FDG imaging. SECTION II: Radiopharmaceutical Products and Technology • Technical principles and functional characteristics of radiopharmaceutical agents. • Radioisotope selection and optimization; production methods and trade-offs. • Analysis of emerging technologies and their probable impact on future markets. SECTION III: Clinical Applications • Discussion of clinical applications for radiopharmaceutical products and technologies. • Options in radiopharmaceutical selection and opportunities in PET imaging. • Analysis of product characteristics, performance benefits and trade-offs. SECTION IV: Current Developments and Emerging Technologies • Description of products in development within each major market segment including nuclear cardiology, neurology, targeted cancer imaging and infection imaging. • Interaction of diagnostic and therapeutic agents, selection of isotopes and new targeting methodologies. • Description of new technologies for diagnostic agents, such as receptor-specific proteins, antibodies and peptides, new cellular viability agents for cardiology, pretargeting in cancer imaging for increased dose delivery, and agents for imaging cellular necrosis. SECTION V: Industry Analysis • Analysis of current suppliers with individual product sales and market shares in 2002 • Market distribution, pricing strategies and new products in the pipeline. • Discussion of marketing goals, product plans, corporate partnerships and new ventures. SECTION VI: End-User Analysis • Analysis of end-user groups and comparative requirements for medical imaging. • Procedure mix and product utilization in hospitals and clinics. SECTION VII: Company Profiles • Background information on companies in the field and review of recent performance. • Discussion of each company's market activities and management strategies 3 ---more---
  4. 4. PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS HISTORICAL AND FORECAST GROWTH OF RADIOPHARMACEUTICAL SALES FROM 1997-2008 COMPARATIVE SALES GROWTH OF DIAGNOSTIC AND THERAPEUTIC RADIO-PHARMACEUTICALS AND BRACHY- THERAPY PRODUCTS FROM 1997-2008 HISTORIC AND FORECAST SALES GROWTH OF DIAGNOSTIC RADIOPHARMACEUTICALS BY PRODUCT GROUP FROM 1997-2008 2002 DIAGNOSTIC RADIOPHARMA- CEUTICAL SALES SUMMARY BY PROCEDURE AND PRODUCT TYPE 2008 DIAGNOSTIC RADIOPHARMA- CEUTICAL SALES SUMMARY BY PROCEDURE AND PRODUCT TYPE HISTORIC AND FORECAST SALES GROWTH OF NUCLEAR CARDIOLOGY AND VASCULAR IMAGING BY PRODUCT CATEGORY FROM 1997-2008 HISTORIC AND FORECAST SALES OF CARDIAC PERFUSION AND BLOOD POOL AGENTS BY PRODUCT FROM 1997-2008 HISTORIC AND FORECAST SALES OF PHARMACOLOGIC STRESSORS FOR CARDIAC IMAGING BY PRODUCT CATEGORY FROM 1997-2008 SALES OF CARDIOLOGY AGENTS FOR MYOCARDIAL VIABILITY, THROMBUS AND VASCULAR IMAGING BY PRODUCT GROUP FROM 1997- 2008 SALES OF GENERAL NUCLEAR MEDICINE PRODUCTS FOR FUNCTIONAL STUDIES AND TARGETED IMAGING FROM 1997-2008 HISTORIC AND FORECAST SALES OF ISOTOPE PRODUCTS FOR FUNCTIONAL IMAGING, BY PRODUCT FROM 1997-2008 HISTORIC AND FORECAST SALES OF TECHNETIUM AND TECHNETIUM KITS FOR GENERAL PURPOSE IMAGING BY PRODUCT CATEGORY FROM 1997-2008 HISTORIC AND FORECAST SALES OF FDG, ANTIBODIES AND PEPTIDES FOR TARGETED CANCER IMAGING BY PRODUCT GROUP FROM 1997-2008 2002 SALES AND MARKET SHARES OF RADIOPHARMACY COMPANIES AND INDEPENDENT NUCLEAR PHARMACIES ANALYSIS OF RADIOPHARMACY REVENUE, COSTS AND GROSS PROFIT IN 2002 DISTRIBUTION OF RADIOPHARMA- CEUTICAL SALES IN THE U.S. IN 2002, MANUFACTURER'S SALES DOLLAR VOLUME BY PRODUCT CATEGORY 2002 SALES OF THALLIUM FOR HEART PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF CARDIOLITE FOR HEART PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF MYOVIEW FOR HEART PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF CARDIOGEN, RUBIDIUM-81 GENERATOR, FOR HEART PERFUSION STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF PERSANTINE FOR PHARMACOLOGIC STRESS, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF ADENOSINE FOR PHARMACOLOGIC STRESS, SUPPLIER AND MARKET SHARE 2002 SALES OF GENERIC DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF PYP- PYROPHOSPHATE KITS FOR HEART IMAGING, RADIOPHARMA-CEUTICAL SUPPLIER AND MARKET SHARE 4 ---more---
  5. 5. PARTIAL LIST OF EXHIBITS─DIAGNOSTIC RADIOPHARMACEUTICALS 2002 SALES OF TECHNETIUM GENERATORS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF MDP AND HDP KITS FOR BONE IMAGING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF TECHNETIUM DTPA KITS FOR AEROSOL LUNG VENTILATION, BRAIN AND KIDNEY SCANS, RADIIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF TECHNETIUM SULFUR COLLOID KITS FOR LIVER SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF MACRO-AGGREGATED ALBUMIN FOR LUNG PERFUSION SCANS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF TECHNETIUM BILIARY AGENTS FOR GALL BLADDER STUDIES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF TECHNESCAN MAG-3 FOR KIDNEY FUNCTION STUDIES, RADIO- MACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF IODINE 131 FOR THYROID IMAGING AND KIDNEY SCANS, RADIO-PHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF I-123 FOR THYROID SCANS, RADIOPHARMACEUTICAL SUPPLIER-, SALES VOLUME AND MARKET SHARE 2002 SALES OF CERETEC FOR BRAIN PERFUSION STUDIES AND WHITE BLOOD CELL LABELING, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF NEUROLITE FOR BRAIN PERFUSION STUDIES, RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF GALLIUM FOR TUMORS, ABSCESSES AND INFLAMMATION, PRODUCT SUPPLIER AND MARKET SHARE 2002 SALES OF XENON FOR LUNG VENTILATION STUDIES,RADIOPHARMA- CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF INDIUM OXINE FOR IMAGING INFLAMMATORY PROCESSES, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF PROSTASCINT FOR IMAGING PROSTATE CANCER, RADIOPHARMA-CEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF CEA SCAN FOR IMAGING COLORECTAL CANCER, RADIOPHARMA- ACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF OCTREOSCAN FOR IMAGING NEUROENDOCRINE TUMORS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF NEOTECT FOR LUNG CANCER, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF INDIUM CHLORIDE FOR COMPOUNDING WITH CANCER IMAGING AGENTS, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE 2002 SALES OF FDG FOR METABOLIC IMAGING IN ONCOLOGY, NEUROLOGY AND CARDIOLOGY, RADIOPHARMACEUTICAL SUPPLIER AND MARKET SHARE COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIESBY HOSPITAL BED SIZE COMPARATIVE UTILIZATION PARAMETERS FOR DIFFERENT IMAGING MODALITIES IN 2002 RELATIVE PROCEDURE VOLUME AMONG DIFFERENT IMAGINGMODALITIES, RALA-TIONSHIP BY HOSPITAL BED SIZE IN 2002 2002 DISTRIBUTION OF NUCLEAR MEDICINE PROCEDURES IN HOSPITALS AND IMAGING CLINICS
  6. 6. THERAPEUTIC RADIOPHARMACEUTICALS: REPORT CONTENTS SECTION I: Market Status, Trends and Forecasts Analysis of current and emerging markets for therapeutic radiopharmaceuticals. Discussion of market prospects by product group and disease category. Review of new products in the pipeline, projections for FDA approval and sales forecasts in all categories to 2008. This includes: • Analysis of market prospects for new targeted radiotherapy agents that have been approved or in development. Applications include lymphoma, colon cancer, lung cancer, bone cancer, myeloma, endocrine cancer and other cancers resistant to traditional therapies. • Projections for new products using novel targeting technologies for treating bone cancer, brain cancer, pancreatic cancer and other cancers that may benefit from these modalities. • Prospects for new radiotherapies employing isotopes optimized for the application with reduced damage to bystander cells, including lutetium-177, holmium-166, rhenium-188, bismuth 213 and astatine-211. • Discussion of product pricing, competitive factors and return on investment. SECTION II: Analysis of Procedure Volume • Discussion of incidence of disease and relationship to potential radiotherapy procedures. Forecast procedure volume by disease category from 2002-2008 with discussion of rationale for these projections. • Comparative procedure volume for brachytherapy by product application including prostate seed implants, endovascular brachytherapy, post-surgical brachytherapy and irradiated microsphere infusion. SECTION III: Radiopharmaceutical Products and Technology • Technical principles and functional characteristics of therapeutic radiopharmaceuticals. • New options in selecting therapeutic isotopes for specific applications. SECTION IV: Current Developments and Emerging Technology • Discussion of new therapeutic radiopharmaceuticals in development, with analysis of technological prospects and potential applications. . • Analysis of product characteristics, performance benefits and trade-offs relative to various therapeutic applications. SECTION V: END-USER ANALYSIS • Analysis of end-user groups and comparative requirements for radiotherapy products. • Procedure mix and product utilization in hospitals and clinics. SECTION VI: Company Profiles • Background information on companies in the field and review of recent performance. • Discussion of each company's market activities and management strategies.
  7. 7. PARTIAL LIST OF EXHIBITS: THERAPEUTIC RADIOPHARMACEUTICALS HISTORIC AND FORECAST SALES GROWTH OF THERAPEUTIC RADIOPHARMA- CEUTICALS FROM 1997-2008 (Graph) COMPARATIVE SALES GROWTH OF DIAGNOSTIC AND THERAPEUTIC RADIOPHARMACEUTICALS AND BRACHYTHERAPY FROM 1997-2008 2002 THERAPEUTIC RADIOPHARMA- CEUTICAL SALES SUMMARY BY PROCEDURE AND PRODUCT TYPE 2008 THERAPEUTIC RADIOPHARMA- CEUTICALS SALES SUMMARYBY PROCEDURE AND PRODUCT TYPE FORECAST SALES OF TARGETED THERAPEUTIC RADIOPHARMACEUTICALS BY DISEASE TYPE FROM 2002-2008 FORECAST SALES OF TARGETED THERAPEUTIC RADIOPHARMACEUTICALS BY DISEASE TYPE FROM 2003-2008 (Graph) FORECAST GROWTH OF TARGETED RADIOTHERAPY PROCEDURES BY TYPE OF DISEASE FROM 2002-2008 FORECAST SALES GROWTH OF LYMPHOMA IMMUNO-THERAPY AGENTS BY MANUFACTURER AND PRODUCT TYPE FROM 2002-2008 FORECAST SALES GROWTH OF LYMPHOMA AGENTS BY PRODUCT TYPE FROM 1997- 2008 (Graph) FORECAST GROWTH OF LYMPHOMA RADIO-THERAPY PROCEDURES BY MANUFACTURER AND PRODUCT TYPE FROM 2002-2008 FORECAST SALES OF THERAPEUTIC RADIOPHARMACEUTICALSFOR COLON CANCER, LUNG CANCER, PROSTATE, LIVER AND SOLID TUMORS BY PRODUCT TYPE FROM 2003-2008 SALES GROWTH OF THERAPEUTIC RADIOPHARMACEUTICALS FOR COLON CANCER, LUNG CANCER, PROSTATE, LIVER AND SOLID TUMORS BY PRODUCT TYPE FROM 2003-2008 (Graph) PROCEDURE GROWTH OF THERAPEUTIC RADIOPHARMACEUTICALS FOR COLON CANCER, LUNG CANCER, PROSTATE, LIVER AND SOLID TUMORS BY PODUCT TYPE FROM 2003-2008 FORECAST SALES OF THERAPEUTIC RADIOPHARMACEUTICALS FOR MYELOMA, MELANOMA, BONE CANCER, AND ENDOCRINE CANCER BY PRODUCT TYPE FROM 2003-2008 FORECAST SALES OF THERAPEUTIC RADIOPHARMACEUTICALSFOR MYELOMA, MELANOMA, BONE CANCER, AND ENDOCRINE CANCER BY PRODUCT TYPE FROM 2003-2008 (Graph) PROCEDURE GROWTH OF THERAPEUTIC RADIOPHARMACEUTICALS FOR MYELOMA, BONE CANCER AND ENDOCRINE CANCER BY PRODUCT TYPE FROM 2003-2008 HISTORIC AND FORECAST SALES GROWTH OF BONE PAIN PALLIATION RADIOTHERAPY AGENTS BY PRODUCT TYPE FROM 1997-2008 HISTORIC AND FORECAST SALES GROWTH OF BONE PAIN PALLLIATION RADIOTHERAPY AGENTS FROM 1997-2008 (Graph) GROWTH OF TARGETED RADIOTHERAPY PROCEDURE VOLUME BY PRODUCT APPLICATION FROM 2002-2008 GROWTH OF BRACHYTHERAPY PROCEDURE VOLUME BY PRODUCT APPLICATION FROM 2002-2008 COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2002 COMPARATIVE UTILIZATION PARAMETERS FOR DIFFERENT IMAGING MODALITIES IN 2002 RELATIVE PROCEDURE VOLUME FOR DIFFERENT IMAGING MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2002
  8. 8. COMPANY PROFILES INCLUDE AMERSHAM HEALTH ANTISOMA, LTD. (UK) BERLEX LABORATORIES CIS BiO-INTERNATIONAL (BERLEX) DIATIDE RESEARCH LABS (BERLEX) BEST MEDICAL INTERNATIONAL BIOSTREAM, INC. BOSTON LIFE SCIENCEOS, INC. BRACCO DIAGNOSTICS C.R. BARD COPHAROS, INC CORDIS DIVISION OF J&J CORIXA CORPORATION CYTOGEN CORPORATION DOW CHEMICAL CO. DRAXIMAGE, INC. DUPONT IMAGING (BRISTOL MYERS) FUJISAWA USA INC. GUIDANT CORPORATION IDEC PHARMACEUTICALS IMAGYN MEDICAL TECHNOLOGIES IMMUNOMEDICS, INC. LYNNTECH, INC. MALLINCKRODT INC. (TYCO) MDS NORDION MENTOR CORPORATION NEORX CORPORATION NORTH AMERICAN SCIENTIFIC, NOVOSTE CORPORATION PALATIN TECHNOLOGIES INC PEREGRINE PHARMACEUTICALS PETNet PHARMACEUTICALS, INC. PROXIMA THERAPEUTICS INC. SIRTEX MEDICAL LTD. (Australian) SYNCOR INT’L (CARDINAL HEALTH) THERAGENICS CORPORATION VITA MEDICAL (Australian) 8
  9. 9. ORDER FORM Report No. 150 — THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS Report No. 160 — THE U.S. MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS Report No. 170 — THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS Each report is priced at $4,500 including postage. Extra copies are priced at $750 each. Please make checks payable to: BIO-TECH SYSTEMS, INC. For wire transfer, make deposit to: BANK OF AMERICA, NEVADA Post Office Box 98600 Las Vegas, Nevada 89193-8600 Routing/ABA #122 400 724 For credit to: BIO-TECH SYSTEMS, INC., Account No. 270 113 178 Mailing Information Name:______________________________Title:_____________________________________ Company:____________________________________________________________________ Address______________________________________________________________________ City:_______________________State________Zip Code__________Country_____________ Telephone_______________________________FAX_________________________________ E-Mail_______________________________________________ P.O. #:______________________________Signature_________________________________ Credit Cards: VISA, MC, AMEX, DISCOVER (Check One) Credit Card No._______________________________________________________________ Expiration: Month_______Year_____Name on Card :_________________________________ Signature____________________________________________________________________ Address for Credit Card Statements________________________________________________ ____________________________________________________________________________ Return to: BIO-TECH SYSTEMS, INC. 4167 W. Pinecrest Circle Las Vegas, Nevada 89121 Telephone: (702) 456-7608 FAX (702) 456-2189 E-Mail: MBurns@biotechsystems.com
  10. 10. ORDER FORM Report No. 150 — THE U.S. MARKET FOR DIAGNOSTIC RADIOPHARMACEUTICALS Report No. 160 — THE U.S. MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS Report No. 170 — THE U.S. MARKET FOR BRACHYTHERAPY PRODUCTS Each report is priced at $4,500 including postage. Extra copies are priced at $750 each. Please make checks payable to: BIO-TECH SYSTEMS, INC. For wire transfer, make deposit to: BANK OF AMERICA, NEVADA Post Office Box 98600 Las Vegas, Nevada 89193-8600 Routing/ABA #122 400 724 For credit to: BIO-TECH SYSTEMS, INC., Account No. 270 113 178 Mailing Information Name:______________________________Title:_____________________________________ Company:____________________________________________________________________ Address______________________________________________________________________ City:_______________________State________Zip Code__________Country_____________ Telephone_______________________________FAX_________________________________ E-Mail_______________________________________________ P.O. #:______________________________Signature_________________________________ Credit Cards: VISA, MC, AMEX, DISCOVER (Check One) Credit Card No._______________________________________________________________ Expiration: Month_______Year_____Name on Card :_________________________________ Signature____________________________________________________________________ Address for Credit Card Statements________________________________________________ ____________________________________________________________________________ Return to: BIO-TECH SYSTEMS, INC. 4167 W. Pinecrest Circle Las Vegas, Nevada 89121 Telephone: (702) 456-7608 FAX (702) 456-2189 E-Mail: MBurns@biotechsystems.com

×